Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (693)	10/22/1999 11:17:00 AM
From: Dr. John M. de Castro	Read Replies (2) of 1494

NTII is eligible for royalties on the sale of memantine for Parkinsons Disease. But, Merz has the rights and the lions share of the royalties. So, it would be cash for NTII, but, we won't get rich from it. On the other hand, it is more data suggesting that memantine is neuroprotective and has many potential applications. AIDS Denentia Complex is one of these applications that NTII would receive the largest share of those royalties. Best regards John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next